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Objectives
To improve the overall accuracy of diagnosis in needle
biopsies of renal masses, especially small renal masses (SRMs),
using fluorescence in situ hybridization (FISH), and to develop
a renal cortical neoplasm classification decision tree based on
genomic alterations detected by FISH.
Patients and Methods
Ex vivo fine needle aspiration biopsies of 122 resected renal
cortical neoplasms were subjected to FISH using a series of
seven-probe sets to assess gain or loss of 10 chromosomes
and rearrangement of the 11q13 locus. Using specimen
(nephrectomy)-histology as the ‘gold standard’, a genomic
aberration-based decision tree was generated to classify
specimens. The diagnostic potential of the decision tree was
assessed by comparing the FISH-based classification and
biopsy histology with specimen histology.
Results
Of the 114 biopsies diagnostic by either method, a higher
diagnostic yield was achieved by FISH (92 and 96%) than
histology alone (82 and 84%) in the 65 biopsies from SRMs
(<4 cm) and 49 from larger masses, respectively. An optimized
decision tree was constructed based on aberrations detected in
eight chromosomes, by which the maximum concordance of
classification achieved by FISH was 79%, irrespective of mass
size. In SRMs, the overall sensitivity of diagnosis by FISH
compared with histopathology was higher for benign
oncocytoma, was similar for the chromophobe renal cell
carcinoma subtype, and was lower for clear-cell and papillary
subtypes. The diagnostic accuracy of classification of needle
biopsy specimens (from SRMs) increased from 80% obtained
by histology alone to 94% when combining histology and
FISH.
Conclusion
The present study suggests that a novel FISH assay developed
by us has a role to play in assisting in the yield and accuracy
of diagnosis of renal cortical neoplasms in needle biopsies in
particular, and can help guide the clinical management of
patients with SRMs that were non-diagnostic by histology.
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Introduction
With increased use of modern imaging techniques, small renal
masses (SRMs) are being identified with greater frequency,
mostly in asymptomatic patients. The patient management
and treatment options available for SRMs (<4 cm) include
active surveillance, thermal ablation, and partial/radical
nephrectomy, the selection of which can be difficult so as to
avoid overtreatment [1,2]. Importantly, more than half of all
renal tumours are incidentally detected SRMs, 15–35% of
which are benign and do not require surgical extirpation [3,4].
Preoperative evaluation of SRMs would help to reduce the
BJU Int 2014; 114: 881–890© 2014 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International | doi:10.1111/bju.12643
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited and is not used for commercial purposes.
number of patients with benign tumours who are subjected
to nephrectomy that can lead to unnecessary urological
complications [5] and, in elderly patients with metastasis,
this could reduce the time to initiation of selective systemic
therapy, depending on tumour subtype [6]. Percutaneous
image-guided needle biopsy of such masses is emerging as a
valuable diagnostic tool and carries minimal risk [7,8];
however, a major challenge with needle biopsy is to obtain
adequate tissue material maintaining cellular architecture
for accurate histopathological diagnosis. Recent studies
indicate that 10–25% of core needle biopsies are rendered
non-diagnostic by histology alone [9,10]. Biopsies obtained by
fine needle aspiration (FNA) have higher diagnostic rates,
although with reduced accuracy [11,12]. Hence, there is a
compelling need to develop ancillary assays that could assist in
the accurate classification of SRMs, guiding subsequent patient
management.
Renal cortical neoplasms originate in the renal cortex and
comprise predominantly malignant RCC (90%) and benign
oncocytoma (OC) (5%) [13]. Amongst RCCs, the clear-cell
RCC (ccRCC) subtype is the most prevalent (∼80–85%), with
papillary (pRCC) and chromophobe RCC (chrRCC) subtypes
contributing ∼5–10% each. Often subtype classification can be
difficult using routine morphology alone, in particular when
distinguishing between OC and chrRCC, and overall ∼6% of
RCC remain ‘unclassified’ [14].With US Food and Drug
Administration approval of targeted agents such as sunitinib
and temsirolimus for the treatment of metastatic ccRCC and
pRCC, respectively, correct subtype classification is highly
desirable. Immunohistochemical markers have variously been
reported and used to assist in subtype classification, but
non-specific staining can be problematic [15].
Genetic alterations have been found to be associated with
each of the main renal cortical neoplasm subtypes and
sometimes with prognostic value [16]. Because of its relative
abundance, ccRCC has been studied most extensively, and
inactivation of the Von Hippel-Lindau (VHL) gene at the
3p25 locus, mostly by deletion but also by mutation and
methylation, is considered to have an aetiological role
[17,18]. Gain of chromosome 5 has been linked with good
prognosis in ccRCC while loss of chromosome arms 4q, 9p
and 14q have been shown to be associated with poor
outcome [19–22]. Gain of chromosomes 7 and 17, mostly
evident as trisomies, and to some extent gain of chromosome
3, are hallmarks of pRCC [23,24]. Widespread monosomies
characterize chrRCC, mostly of chromosomes 1, 2, 6, 10, 13
and 17 [25,26]. OCs often have a nearly diploid genome with
frequent loss of chromosomes 1, 14 and Y [16,20,27].
Rearrangement of CCND1 at 11q13 is also observed in OC
[28,29]. Another subtype of renal cortical neoplasm
exhibiting an Xp11 rearrangement occurs rarely, and mostly
in a younger population [30]; therefore, subtype-associated
genetic alterations offer an additional means by which the
main renal cortical neoplasm subtypes can be classified. A
classification decision tree based on the presence or absence
of the respective aberrations would clearly enhance
implementation in a diagnostic setting.
A few studies have evaluated molecular-cytogenetic
approaches such as quantitative PCR, fluorescence in situ
hybridization (FISH) and comparative genomic hybridization,
for renal tumour classification of needle biopsies [31–35].
Quantitative PCR and comparative genomic hybridization
generally require a higher tumour burden compared
with FISH, and are less well suited for the detection of
rearrangements with relatively dispersed breakpoints [36].
FISH studies on core needle and FNA biopsies have only been
performed to date assessing few aberrations on limited
numbers of specimens [33–35,37]. To fully evaluate the
diagnostic potential of FISH as an ancillary assay to assist in
classification of needle biopsies, a large series of ex vivo FNA
biopsies of resected renal masses were submitted to FISH, with
a comprehensive series of probe sets, to detect gain, loss, and
rearrangement-type aberrations of 11 chromosomes. Using the
resected specimen histopathology as the ‘gold standard’, a
novel classification decision tree was developed for molecular
subtyping of renal cortical neoplasms, based on the observed
genomic alterations in eight chromosomes.
Patients and Methods
Specimens
Ex vivo FNA and core needle biopsies were obtained from 132
resected renal masses from patients undergoing radical or
partial nephrectomy as part of their routine care at the
Memorial Sloan-Kettering Cancer Center, as previously
described [11,38]. Of the 132 masses, 10 were non-renal
cortical neoplasms and hence were excluded from the study.
For the remaining 122, mass size was available (Table S1).
ThinPreps (Hologic, Inc., Bedford, MA, USA) (4–5) were
made available for FISH for each FNA biopsy. After biopsy
classification by FISH (bp-FISH), the histology of the
respective needle core biopsy (bp-histology) and specimen
proper (sp-histology) as assessed by routine haematoxylin and
eosin staining were unblinded. The sp-histology served as the
gold standard (Table S1). Touch preps of adjoining
normal-appearing kidney were obtained from an additional
five male and five female patients with renal cancer to serve as
controls for the establishment of FISH thresholds. The sex of
each patient was made available to afford accurate assessment
of loss of the Y chromosome. All studies were approved by the
institutional review board.
Fluorescence in Situ Hybridization Analysis
A custom-designed series of DNA-FISH probe sets were used,
as detailed in Table 1. For each locus, bacterial artificial
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chromosome clones or plasmids were selected based on the
genomic location and coverage of the locus of interest (Life
Technologies, Grand Island, NY, USA). Individual bacterial
artificial chromosomes/plasmids displaying non-specific
hybridization or chimerism were excluded from the final probe
sets. The individual probes were labelled by nick translation
(Abbott Molecular, Des Plaines, IL, USA) incorporating one of
three fluorochromes: Red 580 dUTP, Green 496 dUTP, or Gold
525 dUTP (ENZO Life Sciences Inc., Farmingdale, NY, USA)
and combined according to Table 1. The ThinPrep and touch
prep slides of each specimen were fixed in Carnoy’s fixative
(3:1, methanol: acetic acid) according to standard procedures
and submitted to the series of hybridizations using an
optimized protocol. Briefly, slides were pretreated with 0.1%
pepsin (Sigma-Aldrich Corp., St. Louis, MO, USA) at 37°C for
30 min and then 50% glycerol/0.1X standard saline citrate (0.1X
SSC) at 90 °C for 3 min. The slides were denatured in 70%
formamide (Amresco LLC, Solon, OH, USA)/2X SSC for 2 min
at 70°C followed by dehydration in 70 and 100% ice-cold
ethanol for 4 min each and air-dried. The DNA-FISH probes
were denatured at 70°C for 8 min, applied to the slides, and
hybridized at 37°C overnight. Post-hybridization washes were
done in 0.1% Tween-20/2X SSC at 45°C for 5 min. Slides were
then counterstained with 4′,6-diamidino-2-phenylindole
in Vectashield anti-fade medium (Vector Laboratories,
Burlingame, CA, USA) and signals visualized on a Zeiss
Axioimager M1 epifluorescence microscope using fluorescence
filter cubes (Chroma Technology, Bellows Falls, VT, USA).
Images were captured and analysed using ISIS software
(MetaSystems,Waltham, MA, USA). For a few specimens
with limited material, slides were re-hybridized once with a
different probe set.
For the normal control touch preps, 100 nuclei were scored
each by two independent readers and the theshold values,
above which specimens would be positive for the respective
gains, losses and rearrangements, were calculated based on
Gaussian statistics [39]. To reach 99% CI, the threshold for
each probe was set at mean value in control (normal kidney)
tissue plus three standard deviations. For the ThinPrep
specimens, a minimum of 50 nuclei were scored for each
specimen and those with <50 scorable nuclei were
considered not scorable. Scoring reproducibility was
evaluated by comparing scores for common probes
hybridized between different probe sets (chr17 and
22) where on average, gain scores differed between
hybridizations by 6.8% (SD = 9.0%) and losses by 4.1%
(SD = 7.2%). The signal patterns were recorded and the
presence of three or more signals for a probe was considered
as gain of that probe. For each probe other than those
localized to chr3 (3p21, 3p25 and 3q11), the presence of
fewer than two signals was considered as loss of that probe.
The score for loss of 3p, 3p21 or 3p25, was the sum of nuclei
containing fewer than two signals of a probe and nuclei
containing a fewer number of signals of the 3p probe with
respect to the 3q11 probe. For 11q13 rearrangement, nuclei
were considered to be positive for rearrangement when
either individual red and/or green signals were detected
along with a yellow (fusion) signal(s) in the same nucleus.
The respective scores obtained for all the 122 FNA biopsies
are shown in Table S1. For subtype classification, major
clones and scoring patterns were taken into account, with the
exception of specimens with overall low scores (<20% cells
with any specific aberration) where classification was based
solely on tabulated scores.
Table 1 Fluorescence in situ hybridization probesets and constituent bacterial artificial chromosomes.
Set Probe (aberration) BAC clones Locus Signal colour
1 3p25 (loss) CTD-2369F5, CTD-3164K3, CTD-2252H8, CTD-3094H19 3p25 (VHL) Green
3p21 (loss) CTD-2542H13, CTD-2653O3 3p21 Red
3q (loss) RP11-259L20, RP11-1133P14, RP11-95J3, RP11-90K16 3q11 Gold
2 5p (gain) RP11-5H13, RP11-193P20, CTD-2201E9, CTD-2001E22 5p13 Green
5q (gain) RP11-21I20, RP11-368O19 5q33 Red
3 Chr3 (gain) RP11-641D5, RP11-659A23, RP11-828P13, RP11-816J6 3q26 Gold
Chr7 (gain) RP11-667F14, RP11-354H2 7q31 Red
Chr17 (gain) CTD-2019C10, RP11-94L15 17q12 Green
4 Chr2 (loss) CTD-2513E3, RP11-384J5, CTD-3049L15, RP11-418E15 2p23 Red
Chr10 (loss) RP11-79A15, RP11-380G5 10q23 Green
Chr22 RP11-71J20, CTD-2505A22 22q11 Gold
5 Chr6 (loss) RP11-528A10, RP11-583F19 6p22 Red
Chr17 (loss) CTD-2019C10, RP11-94L15 17q12 Green
Chr22 RP11-71J20, CTD-2505A22 22q11 Gold
6 5′-CCND1 (rearrangement) RP11-1109B18, RP11-166J17, RP11-729E14 11q13 Red
3′-CCND1 (rearrangement) CTD-3190C8, CTD-2612N12, RP11-109F24 11q13 Green
7 Chr1 (loss) RP11-343F16, RP11-541J2, RP11-480N10 1q23 Red
Chr14 (loss) RP11-521B24, RP5-998D24, RP11-417P24 14q32 Gold
ChrY (loss) Chromosome Yq (1-1)* Yq12 (Satellite III) Green
*Plasmid. BAC, bacterial artificial chromosome; VHL, Von Hippel-Lindau.
Genomic alteration decision tree to subtype renal cortical neoplasms
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Statistical Analysis
Diagnostic yield and accuracy (sensitivity) were calculated
based on the 114 needle biopsy specimens (65 from renal
masses <4 cm and 49 from masses ≥4 cm in size) for which a
renal cortical subtype classification could be obtained by either
histology (bp-histology) or FISH (bp-FISH). For diagnostic
accuracy estimates, sp-histology served as the gold standard.
The percentage concordance of bp-FISH and bp-histology
were calculated according to the sp-histology excluding
non-diagnostic specimens by the respective methodologies.
Results
Diagnostic Yield
Fluorescence in situ hybridization using a panel of seven
combination probe sets (Table 1) was attempted on FNA
material obtained ex vivo from 122 resected renal cortical
neoplasm masses comprising 77 ccRCCs, 19 pRCCs, 14
chrRCCs, 11 OCs and one Xp11-translocation RCC (Table S1).
The mass sizes ranged from 0.6 to 15.5 cm (median, 3.7 cm)
and the masses were stratified into two clinically relevant
groups: 68 of <4 cm (SRMs) and 54 of ≥4 cm. Initially, FISH
was also performed to detect the Xp11 rearrangement, but
was not considered further because of sample availability
limitations and the rarity of this RCC subtype, especially
in the older target population in whom less invasive
procedures would be mostly considered [40,41]. Thus, the
Xp11-translocation RCC was excluded from further analysis.
By histology alone, 27 of the remaining 121 ex vivo core
needle biopsy specimens were non-diagnostic (22%). By FISH
alone, 14 of the matching 121 ex vivo FNA biopsy specimens
(12%) were non-diagnostic. For both methods, the frequency
of non-diagnostic specimens did not differ between SRMs and
larger renal masses. There were seven specimens that were not
diagnostic by either methodology, most likely because of
low cellularity, and were subsequently excluded from
further analyses. Table 2 lists the gold standard histology
classifications of resected specimens (sp-histology) of the final
114 evaluable specimens and the respective diagnostic yield
for each renal cortical neoplasm subtype obtained by histology
and FISH. In SRMs (<4 cm), the FISH-based assay exhibited a
higher diagnostic yield (92%) than did histology alone (82%)
for ex vivo needle biopsies. A similar trend for increased
diagnostic yield by FISH was also observed for larger renal
masses (≥4 cm; Table 2). Importantly, FISH significantly
increased the diagnostic yield over histology (89 vs 44% in
SRMs) of OC which are ideal candidates for preoperative
biopsy evaluation.
Development of a FISH-based Decision Tree for
Renal Cortical Neoplasm Subtyping
Based on the presence/absence of each FISH-detected
genomic aberration (Table 1), FNA biopsies were initially
assigned a renal cortical neoplasm subtype according to a
preliminary decision tree considering gains and losses of 10
chromosomes and one chromosomal rearrangement based on
published cytogenetic studies [16,20,23,27,37,42,43]. After
unblinding of the respective sp-histology, the tree was further
refined to improve the accuracy of FISH-based classification
as shown in Fig. 1. The refined tree classified biopsies on
the basis of gains/losses in seven chromosomes and one
chromosomal rearrangement. A final subtype (bp-FISH)
was then assigned to each specimen according to this tree,
including classification of specimens as ‘abnormal’ if
aberrations were present but did not result in an RCC subtype
classification according to the tree and as ‘normal’ if no
aberrations were detected. Two independent hybridizations
(probe sets 1 and 2; Table 1) were required for the first





bp-histology, n (%) bp-FISH, n (%)
<4 cm masses (SRMs)
ccRCC 37 32 36
pRCC 12 11 10
chrRCC 7 6 6
OC 9 4 8
Total 65 53 (82) 60 (92)
≥4 cm masses
ccRCC 35 27 35
pRCC 6 6 6
chrRCC 6 6 4
OC 2 2 2
Total 49 41 (84) 47 (96)
bp-FISH, biopsy classification by fluorescence in situ hybridization; bp-histology, needle core biopsy histology; ccRCC,
clear-cell RCC; pRCC, papillary RCC; chrRCC, chromophobe RCC; OC, oncocytoma.
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decision point in the tree wherein most ccRCCs were
classified and, as expected, included loss of the VHL locus
characteristic of ccRCC [20]. Representative FISH images for
specimen K-126 (sp-histology: ccRCC) which exhibited loss of
3p (3p25 and 3p21) are shown in Fig. 2A, which, according to
the tree, was consistent with classification as ccRCC.When a
specimen could not be classified based on these aberrations,
then presence/absence calls were required from probe set 6 to
detect rearrangement of the CCND1 locus at 11q13, observed
in OC. Such was the case for specimen K-38 (Fig. 2B) which
was correctly classified as OC. The results of hybridization of
probe sets 3–5 completed classification of all malignant RCC,
including pRCC exemplified by specimen K-13 (sp-histology:
pRCC) which showed gain of chr17 (probe set 3), typical of
this subtype (Fig. 2C). Additional aberrations were observed in
pRCCs, such as gain of chr7 in specimen K-13 (Fig. 2C), but
because of their presence in multiple subtypes, inclusion in
the tree resulted in reduced classification accuracy. Loss of
chromosomes is often observed in chrRCC, in particular chr2,
6, 10 and 17 as assessed in probe sets 4 and 5, as evidenced in
chrRCC specimen K-94 (Fig. 2D,E). A final hybridization
(probe set 7) was required to classify remaining OC
specimens. Specimen K-53 (female) was representative of
OC specimens classified in this manner (Fig. 2F) showing
loss of chr1. Loss of chrY and 14 were not included in the
classification of OC, because of the frequent detection
of aberrations involving these chromosomes in other
subtypes.
Concordance of bp-FISH and bp–Histology
with sp-Histology
Of the 107 renal cortical neoplasm biopsies for which a
FISH-based classification was obtained (bp-FISH), the optimum
concordance achieved using the refined tree was 79% (84/107,
Table 3). Nine of the misclassifications were in larger masses
(19%), occurring at a similar frequency to that obtained for
SRMs (23%). Of the 23 misclassified specimens, 15 were frank
misclassifications.Another eight specimens of those misclassified
(spread evenly across SRMs and larger masses) exhibited either
no aberrations or low-level clonal aberrations (<20% of cells)
including aberrations not specifically scored for subtyping. This
could reflect low tumour burden in these biopsies. Indeed, two of
these were non-diagnostic and another ‘unclassified’ by routine
pathology of the needle biopsy.Among the correctly classified
specimens, there were seven specimens with similar low levels
of clonal aberrations, of which three were non-diagnostic by
histology. For such borderline specimens with <20% clonal
aberrations, more accurate classification could in general be
achieved by scoring additional cells to increase the confidence in
the presence/absence calls of each abnormality. The bp-histology
showed 97% (91/94) concordance with sp-histology for the 94
renal cortical neoplastic diagnostic specimens, with one of the
three misclassifications occurring in SRMs.
Table 3 also lists the concordance of classification of
diagnostic biopsies by histology alone and by FISH alone for
each of the four renal cortical neoplasm subtypes. It is evident
Fig. 1 Classification decision tree for fluorescence in situ hybridization (FISH)-based subtyping of renal cortical neoplasms. Specimens were assigned a
renal tumour subtype based on the presence or absence of chromosomal aberrations (gain/loss/rearrangements) detected using the respective FISH
probe sets according to the tree. At each decision point, if no classification could be assigned (No Call), then the results of the next hybridization(s)
were considered. bp-FISH, biopsy classification by FISH.
Set 1: 3p25, 3p21, 3q (3q11)
Set 2: 5p, 5q
Loss of 3p25 ccRCC
Loss of 3p21 with gain of 5q ccRCC
Loss of 3p21 without gain of 5q OC
Loss of 3p (3p25 and 3p21) ccRCC
Loss of 3q and gain of 5q ccRCC
Set 7: chr1, chr14, chrY Loss of chr1 OC





Set 3: chr7, chr17, chr3 (3q26)
Set 4, 5: chr2, chr6, chr10, chr17
Loss of chr3 without 2 or more chrRCC losses ccRCC
Gain of chr5 without gain of chr17 and 3, or 2 or more chrRCC losses ccRCC
Two or more chrRCC losses chrRCC
Gain of chr17 pRCC
No Call
Set 6: t:(11q13) Rearrangement OC
FISH Probe Set Chromosome Aberrations Classification (bp-FISH)
Genomic alteration decision tree to subtype renal cortical neoplasms
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that histology outperformed FISH in each of the four
subtypes. The reduced concordance of ccRCC classification
by FISH was mostly the result of misclassification as pRCC
(seven of 11 specimens). Interestingly, for five of these
specimens, large clonal populations of cells showed gain of
chr3, 5, and 17 (probe sets 2 and 3) but none showed loss of
3p25 (VHL) or 3p, scored relative to 3q11 in probe set 1.
Examination of the scoring patterns of probe set 1 for these
five specimens revealed no gain of 3p25, 3p21, or 3q11 loci,
distinct from that found in probe set 3 for the 3q26 locus. This
is exemplified by specimen K-105 in Fig. 3. Thus, relative to
3q26, these five specimens exhibited loss of 3p and 3q11,
resulting in the correct classification of the specimens as
ccRCC. Such segmental duplication of 3q has previously been
Fig. 2 Representative fluorescence in situ hybridization (FISH) images of ex vivo renal mass FNA biopsies showing major clonal signal patterns. (A)
Nuclei from specimen K-126 exhibiting 3p loss (3p21-red [R] and 3p25-green [G]) with respect to 3q11 (3q11-gold [Go]), consistent with clear-cell RCC
subtype. (B) Specimen K-38 nuclei showing 11q13 rearrangement with separated 5′-CCND1(red) and 3′-CCND1(green) signals and one intact normal
fusion signal (yellow [F]). (C) Specimen K-13 (papillary RCC) displaying gain of chr7 (red) and 17 (green), with normal copy number of 3q26 (gold).
Specimen K-94 showing loss of chr2 (red) and 10 (green) in (D) and loss of chr6 in (E), classified as chromophobe RCC. (F) OC specimen K-53













Table 3 Concordance of biopsy classification by needle core biopsy






bp-Histology % bp-FISH %
ccRCC 59/59 100 60/71 85
pRCC 16/17 94 11/16 69
chrRCC 11/12 92 6/10 60
OC 5/6 83 7/10 70
Total 91/94 97 84/107 79
FISH, fluorescence in situ hybridization; bp-FISH, biopsy classification by FISH;
bp-histology, needle core biopsy histology; sp-histology, specimen histology; ccRCC,
clear-cell RCC; pRCC, papillary RCC; chrRCC, chromophobe RCC; OC, oncocytoma.
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reported in ccRCC [44]. For the remaining two ccRCCs
misclassified as pRCC, gains of 3p25, 3p21, and 3q11 were
found, and it is possible in these cases that VHL was inactivated
by other mechanisms such as mutation or methylation rather
than deletion [17,18]. Three of the five misclassified pRCCs,
exhibited alterations consistent with ccRCC (one with
<20% clonal abnormalities) but no common reason for
misclassification was evident. Three of the four misclassified
chrRCCs, were called ccRCC, of which one had low tumour
burden. Another was from a patient with Birt-Hogg-Dube
syndrome, wherein mutations in FLCN predispose carriers to
chromophobe/oncocytic/hybrid renal tumours [45]. It is unclear
if the genomic alterations associated within the Birt-Hogg-Dube
subtype of chrRCC are similar to those observed in sporadic
chrRCC, perhaps explaining the misclassification by FISH. One
other chrRCC was also misclassified by histology. For OC,
three were misclassified by FISH, one as a result of low tumour
burden.
Diagnostic Accuracy
The diagnostic accuracy of classification was calculated for
the 114 evaluable renal cortical neoplasm biopsies by FISH
(bp-FISH) and histology (bp-histology) inclusive of
non-diagnostic specimens relative to the resected specimen
histology (sp-histology) and stratified according to mass size
(Table 4). Across all the evaluable specimens obtained from
SRMs, histology and FISH assays yielded similar overall
diagnostic accuracies when considered individually: 79% by
histology vs 71% by FISH; however, on combining the results
obtained by FISH with those obtained by histology alone, the





Fig. 3 Segmental aneuploidy of chr3 in clear-cell
RCC as revealed by fluorescence in situ
hybridization (FISH). Representative FISH images
of probe sets 1 (A) and 3 (B) are shown for the
specimen K-105. Major clonal signal patterns are
listed below each image.





bp-histology, n (%) bp-FISH, n (%) bp-histology+bp-FISH,
n (%)
<4 cm masses (SRMs)
ccRCC 37 32 28 36
pRCC 12 11 7 12
chrRCC 7 5 5 6
OC 9 4 6 7
Total 65 52 (80) 46 (71) 61 (94)
≥4 cm masses
ccRCC 35 27 32 35
pRCC 6 5 4 5
chrRCC 6 6 1 6
OC 2 1 1 2
Total 49 39 (80) 38 (78) 48 (98)
Combined total 114 91 (80) 84 (74) 109 (96)
FISH, fluorescence in situ hybridization; bp-FISH, biopsy classification by FISH; bp-histology, needle core biopsy histology; sp-histology, specimen histology; ccRCC, clear-cell RCC;
pRCC, papillary RCC; chrRCC, chromophobe RCC; OC, oncocytoma.
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specimens from SRMs increased from 80%, obtained by
histology alone, to 94% (Table 4). A similar increase in
combined diagnostic accuracy was also evident for biopsies
from renal masses ≥4 cm. In SRMs, the overall diagnostic
accuracy by FISH was improved for OC, was similar for
chrRCC, and lower for ccRCC and pRCC subtypes with
respect to histopathology. Across all masses, the sensitivity
of diagnosis of ccRCC was similar for histology and FISH.
Histology was more sensitive in the classification of pRCC
and chrRCC than FISH, but the reverse was evident for OC.
Except for ccRCC, FISH yielded similar overall specificities to
those for histology (Table S2).
Discussion
Use of image-guided needle biopsies has increased in recent
years for diagnostic evaluation of a variety of cancers to assist in
clinical management, including diagnosis of SRMs to guide
appropriate intervention. Risk stratification of SRMs has
benefited from core and FNA biopsies obtained by minimally
invasive procedures for morphological examination, when
compared with imaging alone [1,6]; however, working with
such biopsy material is challenging, largely because of
insufficient sample cellularity and damaged tissue integrity.
Additionally, in the case of FNA biopsies, cytology, while useful
to distinguish benign from malignant lesions, has reduced the
ability to differentiate non-ccRCC subtypes [11]. Depending on
the clinical need, molecular-cytogenetic methodologies offer an
additional diagnostic tool to assist in specimen characterization.
In the present study, the potential of FISH to serve as an
adjunctive assay in the diagnostic classification of needle
biopsies of renal cortical neoplasms was explored. A large panel
of ex vivo FNA biopsies from both SRMs and larger renal
masses was subjected to a series of seven FISH probeset
hybridizations designed to assess genomic abnormalities
commonly found in each of the four subtypes of renal cortical
neoplasms. The FISH assay was found to have the potential for
an overall higher diagnostic yield than morphology alone in
the case of SRMs as well as larger renal masses (≥4 cm).
A novel classification decision tree was built based on the
presence/absence of genomic abnormalities observed in eight
chromosomes, and according to the tree, the overall sensitivity
of classification of FISH vs morphology were similar for ccRCC,
lower for chrRCC and pRCC, but higher for OC. Notably,
inclusion of the FISH-based assay and algorithm for renal
cortical neoplasm subtyping increased the overall diagnostic
accuracy by 14% from morphology alone for SRMs. In addition,
application of this assay to those RCC specimens that remain
‘unclassified’ by routine pathology would clearly assist in RCC
subtyping for therapy guidance. Before the present study, only
few others had evaluated FISH in the classification of renal
cortical neoplasms in needle biopsies but with much reduced
sample numbers and assessing fewer genomic aberrations
[33,35].
Multiple genomic abnormalities have been reported to be
associated with the different renal cortical neoplasm subtypes
[33,37,42,46]. The panel of probes in the present study
were designed to detect gains/losses of 10 chromosomes
(chromosomes 1, 2, 3 [four loci], 5 [two loci], 6, 7, 10, 14, 17,
and Y) and rearrangement of the 11q13 locus. The final
algorithm that was built required fewer probes comprising
chromosomes 1, 2, 3 (three loci), 5q, 6, 10, and 17 and
rearrangement at 11q13. This is clearly an important
consideration for specimens such as needle biopsies
with limited tissue availability. Feasibly, as few as four
hybridizations (three probes per hybridization) would be
sufficient to assess the genomic aberrations required for
classification. A sequential series of the four hybridizations
could also potentially be invoked where, if biopsies exhibit
alterations in chromosomes 3 and 5 according to the tree that
permit classification at the first decision point (Fig. 1), then
no further hybridizations would be required. In general, the
chromosomal abnormalities in the final algorithm comprised
those reported in the literature for specific subtypes.
Interestingly, however, deletion at the 3p21 locus was found to
be associated with OC and was observed in two of the 10 OC
specimens as a classifying abnormality when observed without
the gain of 5q that is commonly detected in ccRCC. Loss
of heterozygosity at 3p21 in OC has been reported in one
previous study, although the target gene and exact role in this
benign neoplasm is unclear [47]. Validation of this novel
genomic marker to assist in classification of OC is required
in a larger sample set. In ccRCC, mutational inactivation of
the PBRM1 gene mapped to 3p21 has been implicated in
tumorigenesis and also recently suggested to be associated
with longer overall survival [48].
Despite optimization of the decision tree, FISH alone was not
found to be as accurate in classification of needle biopsies
as morphology. This was because of low clonal tumour
populations, inability to correctly identify miscellaneous
renal neoplasms (other than RCC and OC), and frank
misclassifications. The first problem could be addressed by
increasing the number of nuclei scored in biopsies with low
levels of detected abnormalities. Notably, in the present study,
the numbers of nuclei scored were similar to other studies
[33,35]. The second is an inherent pitfall of the assay
attributable to the assessment only of chromosomal anomalies
frequent in renal cortical neoplasms and supports the
role of FISH as an ancillary test to morphology to assist in
classification rather than a stand-alone test using the current
panel of probes. The last reason for misclassification could be
accounted for by segmental duplication of chr3 (could be
avoided by using a 3q26 probe for scoring 3p loss), alterations
in target genes either below the resolution of detection by
FISH, at other discriminatory loci not in the current panel,
or by other genetic or epigenetic mechanisms of gene
activation/inactivation. This is exemplified in ccRCC, where
Gowrishankar et al.
© 2014 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International888
VHL can also undergo inactivation by mutation and/or
methylation [17,18]. Recent studies have clearly underscored
the role of such mechanisms, not only in renal cancer
aetiology but also in metastasis [49].
Image-guided needle biopsies of renal masses are currently
recommended for poor surgical candidates and elderly
patients with comorbidities [50]. Accurate diagnosis of the
limited available tissue is highly desirable, especially in the
context of SRMs, wherein about one third of masses were
diagnosed to be benign. About 20% of core needle biopsies in
the present study were non-diagnostic by histopathology
alone, reducing the potential for this procedure to assist in
patient management. A supporting role for FISH in renal
tumour classification of needle biopsies was demonstrated in
this ex vivo study to enhance the overall diagnostic accuracy
by 16% compared with histopathology alone. The greatest
diagnostic potential for the FISH assay was evident for
SRMs that were non-diagnostic by core biopsy histology.
The FISH assay also exhibited the potential to diagnose
‘unclassified-RCC’ specimens, exemplified by specimen K-67
that was correctly classified by FISH as OC. In addition,
FISH was found to be particularly superior for the detection
of OC, a benign subtype for which active surveillance is
recommended, avoiding overtreatment, an important
consideration in an older frail population. The diagnostic
accuracy of FISH testing of core needle biopsies instead of
FNA biopsies requires further evaluation; however, given the
overall limited tissue availability of needle biopsy specimens,
it is feasible that other DNA-based assays, including a
comparative genomic hybridization to permit evaluation of
genomic gain/loss at additional loci not targeted by FISH,
targeted massively parallel sequencing for select genes, and
methylation, or a combination thereof with FISH could be
implemented to improve the overall accuracy of diagnosis.
The costs of performing and the reporting times of these
higher complexity assays become important considerations in
routine renal mass patient care and management. Comparison
of the diagnostic accuracy of these methodologies in a clinical
setting is warranted.
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